Canopy Growth boosts M&A transparency in wake of Aphria fiasco

Cash-rich Canopy Growth bought global vaporizer leader Storz & Bickel for 220 million Canadian dollars ($160 million) in a bid to improve its portfolio of intellectual property.

The all-cash deal is also intended to position Canopy to capitalize on the next wave of federally regulated products in Canada and around the world, the Smiths Falls, Ontario company said in a news release.

It is the first significant international acquisition in the Canadian cannabis sector since a report earlier this week alleged that rival licensed producer Aphria massively overpaid for assets in the Caribbean and Latin America to benefit company insiders. Aphria disputes those claims.

Canopy had not planned to disclose the price of the acquisition, because “it hurts us in future negotiations and it allows our competitors to get a sense of the market,” a source at the company told Marijuana Business Daily on condition of anonymity.

“Because there is pressure out there for transparency, we decided to put that in.”

Canopy also disclosed that Greenhill & Co. Canada acted as financial adviser and provided a fairness opinion to its board during the acquisition process.

Storz & Bickel has an IP portfolio that includes 17 filed patents, and the company has exported devices to 50 markets around the world.

The Tuttlingen, Germany-based firm employs about 100 people and designs and manufactures medically approved vaporizers.

The company’s founders, Markus Storz and Jürgen Bickel, will remain as a part of the organization.

Canopy declined to disclose Storz & Bickel’s annual revenue.

“We view this as a marquee acquisition of the most recognized technology company in the industry,” Canopy co-CEO Bruce Linton said in the release. “This Company is well positioned for the next wave of federally regulated products in Canada beyond dried flower and edible oils.”

As of Sept. 30, Canopy had cash and cash equivalents of CA$429 million.

Canopy Growth’s shares trade on the New York Stock Exchange under the ticker symbol CGC and on the Toronto Stock Exchange as WEED.

Matt Lamers can be reached at [email protected]

To sign up for our weekly international marijuana business newsletter, click here.

7 comments on “Canopy Growth boosts M&A transparency in wake of Aphria fiasco
    • Sergio Toscano on

      Putting money at work in infrastructure is the safest way to reap future sustainable profits. Be patient, better things are coming.

      Reply
    • Bobby on

      it won’t due to bunk bone dried weed.

      Gamma irradiation burns terpenes and stops curing.

      Canadians know cannabis and this junk weed is not cutting it…

      Reply
    • Jimmy fallon on

      The key is to invest before projections are placed on the company…..I bought canopy when it was bedrocan. ….Next its hemp plays…

      Reply
  1. Bobby on

    Crappy Growth Gamma irradiated bunk cannabis does not sell well

    Radiation burns terpenes and stops curing

    Canadian don’t bone dry cannabis

    They are doomed

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *